Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry

被引:49
作者
Nirogi, RVS [1 ]
Kandikere, VN [1 ]
Shukla, M [1 ]
Mudigonda, K [1 ]
Maurya, S [1 ]
Boosi, R [1 ]
机构
[1] Suven Life Sci ltd, Biophramaceut Res, Hyderabad 500034, Andhra Pradesh, India
关键词
D O I
10.1002/rcm.2497
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, sensitive and rapid high-performance liquid chromatography/positive electrospray ionization tandem mass spectrometry method was developed and validated for the assay of clopidogrel in human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by mass spectrometry in the multiple reaction monitoring mode using the respective [M+H](+) ions, m/z 322/212 for clopidogrel and m/z 264/154 for the internal standard. The assay exhibited a linear dynamic range of 5-6000 pg/mL for clopidogrel in human plasma. The lower limit of quantification was 5 pg/mL with a relative standard deviation of less than 8%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1695 / 1700
页数:6
相关论文
共 25 条
  • [1] Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study
    Borges, NCD
    Mendes, GD
    Borges, A
    de Oliveira, SE
    Barrientos-Astigarraga, RE
    De Nucci, G
    [J]. JOURNAL OF MASS SPECTROMETRY, 2004, 39 (12): : 1562 - 1569
  • [2] Caplain H, 1999, SEMIN THROMB HEMOST, V25, P25
  • [3] The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
    Clarke, TA
    Waskell, LA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 53 - 59
  • [4] Clopidogrel
    Coukell, AJ
    Markham, A
    [J]. DRUGS, 1997, 54 (05) : 745 - 750
  • [5] Clopidogrel: The future choice for preventing platelet activation during coronary stenting?
    Gurbel, PA
    O'Connor, CM
    Cummings, CC
    Serebruany, VL
    [J]. PHARMACOLOGICAL RESEARCH, 1999, 40 (02) : 107 - 111
  • [6] KSYCINSKA H, 2005, J PHARM BIOMED ANAL
  • [7] Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography mass spectrometry
    Lagorce, P
    Perez, Y
    Ortiz, J
    Necciari, J
    Bressolle, F
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1998, 720 (1-2): : 107 - 117
  • [8] Lainesse A, 2004, ARZNEIMITTELFORSCH, V54, P600
  • [9] Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
    Matuszewski, BK
    Constanzer, ML
    Chavez-Eng, CM
    [J]. ANALYTICAL CHEMISTRY, 2003, 75 (13) : 3019 - 3030
  • [10] McEwen J, 1999, SEMIN THROMB HEMOST, V25, P47